ClinicalTrials.gg
CompletedNCT03525574Updated Sep 24, 2025Results posted

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 110 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
Largest of 23
507 · median 120
Started
2018
with 1 other
Phase 3
19 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one has the largest enrollment, is one of 2 that started in 2018, is one of 19 in phase 3, and was the 2nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed study drug treatment in a parent study i.e.VX17-445-102 (NCT03525444) and VX17-445-103 (NCT03525548); or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.

Exclusion criteria

Exclusion Criteria:

  • History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator.
  • Current participation in an drug trial (other than a parent study)

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Treatment Period: Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks. Extension Period: Participants from certain countries participated in extension period and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination (FDC) tablet for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 196

Secondary outcomes

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  2. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  3. Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set

    Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  4. Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set

    Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  5. Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline at Week 192

  6. Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline at Week 192

  7. Time to First PEx for 102/105 Efficacy Set

    Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline at Week 192

  8. Time to First PEx for 103/105 Efficacy Set

    Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline at Week 192

  9. Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  10. Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  11. Absolute Change in BMI Z-score for 102/105 Efficacy Set

    BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  12. Absolute Change in BMI Z-score for 103/105 Efficacy Set

    BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  13. Absolute Change in Body Weight for 102/105 Efficacy Set

    This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  14. Absolute Change in Body Weight for 103/105 Efficacy Set

    This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  15. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

  16. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.

    Time frame: From Baseline at Week 192

07

Results

Posted May 8, 2024

Participant flow

The study was conducted as a single period i.e. treatment period in countries including United States (US) with commercially-available ELX/TEZ/IVA. The regional protocol for other countries without commercially-available ELX/TEZ/IVA was amended so that participants in these countries had the opportunity to participate for up to an additional 48 weeks in extension period.

Participant flow — Overall Study
MilestoneELX/TEZ/IVAAdditional Participants for Cumulative TC Efficacy Set
Started5073
Open-label safety set (ol-ss)5060
Ol-fas 102/1053990
Ol-fas 103/1051070
Cumulative triple combination (tc) efficacy set 102/1054003
Cumulative tc efficacy set 103/1051070
Completed3540
Not completed1533
Withdrew: Adverse event150
Withdrew: Withdrawal of consent (not due to ae)180
Withdrew: Lost to follow-up40
Withdrew: Commercial drug is available for participant480
Withdrew: Death10
Withdrew: Other non-compliance20
Withdrew: Physician decision60
Withdrew: Other580
Withdrew: Enrolled but never dosed10
Withdrew: Not enrolled in 105 study03

Outcome measures

PrimaryTreatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 up to Week 196
Reported as:
Count of participants · Participants
Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsELX/TEZ/IVA
Participants With TEAEs504
Participants With SAEs175
SecondaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set
percentage pointsELX/TEZ/IVA
Placebo-ELX/TEZ/IVA15.3 ± 0.8
ELX/TEZ/IVA-ELX/TEZ/IVA13.8 ± 0.8
SecondaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set
percentage pointsELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA10.9 ± 1.3
ELX/TEZ/IVA-ELX/TEZ/IVA10.7 ± 1.3
SecondaryAbsolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set

Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set
millimole per liter (mmol/L)ELX/TEZ/IVA
Placebo-ELX/TEZ/IVA-47.0 ± 1.6
ELX/TEZ/IVA-ELX/TEZ/IVA-45.3 ± 1.6
SecondaryAbsolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set

Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · mmol/L
Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set
mmol/LELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA-48.2 ± 3.8
ELX/TEZ/IVA-ELX/TEZ/IVA-48.2 ± 3.5
SecondaryNumber of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline at Week 192
Reported as:
Number · PEx events
Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set
PEx eventsELX/TEZ/IVA
Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set174
SecondaryNumber of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline at Week 192
Reported as:
Number · PEx events
Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set
PEx eventsELX/TEZ/IVA
Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set43
SecondaryTime to First PEx for 102/105 Efficacy Set

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline at Week 192
Reported as:
Median · days
Time to First PEx for 102/105 Efficacy Set
daysELX/TEZ/IVA
Time to First PEx for 102/105 Efficacy SetNA (NA to NA)
SecondaryTime to First PEx for 103/105 Efficacy Set

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline at Week 192
Reported as:
Median · days
Time to First PEx for 103/105 Efficacy Set
daysELX/TEZ/IVA
Time to First PEx for 103/105 Efficacy SetNA (NA to NA)
SecondaryAbsolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · kilogram per meter square (kg/m^2)
Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set
kilogram per meter square (kg/m^2)ELX/TEZ/IVA
Placebo-ELX/TEZ/IVA1.81 ± 0.16
ELX/TEZ/IVA-ELX/TEZ/IVA1.74 ± 0.16
SecondaryAbsolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · kg/m^2
Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set
kg/m^2ELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA1.72 ± 0.24
ELX/TEZ/IVA-ELX/TEZ/IVA1.85 ± 0.22
SecondaryAbsolute Change in BMI Z-score for 102/105 Efficacy Set

BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · z-score
Absolute Change in BMI Z-score for 102/105 Efficacy Set
z-scoreELX/TEZ/IVA
Placebo-ELX/TEZ/IVA0.24 ± 0.09
ELX/TEZ/IVA-ELX/TEZ/IVA0.18 ± 0.09
SecondaryAbsolute Change in BMI Z-score for 103/105 Efficacy Set

BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · z-score
Absolute Change in BMI Z-score for 103/105 Efficacy Set
z-scoreELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA0.36 ± 0.14
ELX/TEZ/IVA-ELX/TEZ/IVA0.24 ± 0.15
SecondaryAbsolute Change in Body Weight for 102/105 Efficacy Set

This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · kg
Absolute Change in Body Weight for 102/105 Efficacy Set
kgELX/TEZ/IVA
Placebo-ELX/TEZ/IVA6.6 ± 0.5
ELX/TEZ/IVA-ELX/TEZ/IVA6.0 ± 0.5
SecondaryAbsolute Change in Body Weight for 103/105 Efficacy Set

This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · kg
Absolute Change in Body Weight for 103/105 Efficacy Set
kgELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA6.1 ± 0.8
ELX/TEZ/IVA-ELX/TEZ/IVA6.3 ± 0.7
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set
units on a scaleELX/TEZ/IVA
Placebo-ELX/TEZ/IVA15.3 ± 1.5
ELX/TEZ/IVA-ELX/TEZ/IVA18.3 ± 1.5
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.

Time frame:
From Baseline at Week 192
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set
units on a scaleELX/TEZ/IVA
TEZ/IVA-ELX/TEZ/IVA14.8 ± 2.6
ELX/TEZ/IVA-ELX/TEZ/IVA17.6 ± 2.4

Adverse events

Collected over Adverse events (AE) are reported separately for both Periods. Treatment period covers 1st dose till 196 weeks in treatment period; extension period covers 1st dose in extension period till safety follow-up or end of study, whichever occurs first. The actual total duration for AE collection is up to 222 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: ELX/TEZ/IVA1/506 (0.2%)175/506 (34.6%)501/506 (99%)
Extension Period: ELX/TEZ/IVA0/11 (0%)0/11 (0%)7/11 (63.6%)
Most frequent serious events
Showing 10 of 150
Most frequent serious events
EventTreatment Period: ELX/TEZ/IVAExtension Period: ELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations83/5060/11
HaemoptysisRespiratory, thoracic and mediastinal disorders11/5060/11
Distal intestinal obstruction syndromeGastrointestinal disorders9/5060/11
InfluenzaInfections and infestations7/5060/11
ConstipationGastrointestinal disorders6/5060/11
PneumoniaInfections and infestations6/5060/11
Intestinal obstructionGastrointestinal disorders5/5060/11
Alanine aminotransferase increasedInvestigations5/5060/11
Aspartate aminotransferase increasedInvestigations5/5060/11
NephrolithiasisRenal and urinary disorders5/5060/11
Most frequent other events
Showing 10 of 66
Most frequent other events
EventTreatment Period: ELX/TEZ/IVAExtension Period: ELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders231/5060/11
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations224/5063/11
HeadacheNervous system disorders178/5060/11
COVID-19Infections and infestations168/5060/11
Oropharyngeal painRespiratory, thoracic and mediastinal disorders166/5061/11
NasopharyngitisInfections and infestations154/5060/11
PyrexiaGeneral disorders147/5060/11
Sputum increasedRespiratory, thoracic and mediastinal disorders127/5060/11
Upper respiratory tract infectionInfections and infestations120/5061/11
FatigueGeneral disorders118/5060/11

Baseline characteristics

All participants who received at least one dose of the study drug in this open label study were included in the baseline characteristics.

Age, Continuous
Age, Continuous(years)ELX/TEZ/IVA
Mean26.7 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female251
Male255
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Hispanic or Latino21
Not Hispanic or Latino460
Not collected per local regulations25
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
White470
Black or African American4
American Indian or Alaska Native1
Other3
Not collected per local regulations25
Multiple3
08

Study locations

110 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Miller Children's Hospital / Long Beach Memorial
    Long Beach, California 90806, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Valley Children's Hospital
    Madera, California 93636, United States
  • Kaiser Permanente
    Oakland, California 94611, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • UCSF Gateway Medical Center
    San Francisco, California 94143, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of Florida, Shands Hospital
    Gainesville, Florida 32610, United States
  • Joe DiMaggio Cystic Fibrosis & Pulmonary Center
    Hollywood, Florida 33021, United States
  • Nemours Children's Specialty Care
    Jacksonville, Florida 32207, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Tampa General Hospital Cardiac and Lung Transplant Clinic
    Tampa, Florida 33606, United States
  • Children's Specialty Services at North Druid Hills
    Atlanta, Georgia 30324, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Cystic Fibrosis Center, Children's Hospital of Illinois at OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Maine Medical Partners
    Portland, Maine 04102, United States
  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center
    Boston, Massachusetts 02114, United States
  • Harper University Hospital
    Detroit, Michigan 48201, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • Billings Clinic Hospital
    Billings, Montana 59101, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • UNM Clinical and Translational Science Center
    Albuquerque, New Mexico 87131, United States
  • The Cystic Fibrosis Center, Mount Sinai Beth Israel
    New York, New York 10003, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • UNC Marsico Clinical Research Center
    Chapel Hill, North Carolina 27517, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • UC Health Holmes
    Cincinnati, Ohio 45220, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children's Hospital
    Dayton, Ohio 45404, United States
  • ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
    Toledo, Ohio 43606, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
  • University of Virginia Primary Care Center
    Charlottesville, Virginia 22908, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Children's Hospital of Richmond at VCU, Children's Pavilion
    Richmond, Virginia 23298, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • University of Wisconsin Hospitals and Clinics
    Madison, Wisconsin 53792, United States
  • CTSI Adult Translational Research Unit/Medical College of Wisconsin/Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Women & Children's Hospital
    North Adelaide, Australia
  • The Royal Children's Hospital
    Parkville, Australia
  • Mater Misericordiae Ltd
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • Westmead Hospital
    Westmead, Australia
  • University of Graz
    Graz, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, Austria
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, Austria
  • Medizinische Universitat Wien
    Vienna, Austria
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Brussel - Campus Jette
    Brussels, Belgium
  • UZ Antwerpen
    Edegem, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • University of Calgary Medical Clinic of the Foothills Medical Centre
    Calgary, Canada
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Canada
  • Centre Hospitalier De L'Universite Laval
    Québec, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia's Children's Hospital
    Vancouver, Canada
  • St. Paul's Hospital
    Vancouver, Canada
  • Fakultni Nemocnice Brno
    Brno, Czechia
  • Fakultni nemocnice v Motole
    Prague, Czechia
  • Centre Hospitalier Lyon Sud
    Benite Cedex, France
  • Groupe Hospitaler Pellegrin, CHU De Bordeaux
    Bordeaux, France
  • CHU Marseille - Hopital Nord
    Marseille, France
  • CHU de Nice - Hopital Pasteur
    Nice, France
  • Hopital Cochin
    Paris, France
  • CHU de Rouen - Hopital Charles Nicolle
    Rouen, France
  • Hopital Foch (Suresnes), Hopital Foch, Adultes
    Suresnes, France
  • Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital
    Erlangen, Germany
  • Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin
    Giessen, Germany
  • Hannover Medical School
    Hanover, Germany
  • Johannes Gutenberg-Universitaet
    Mainz, Germany
  • Dr. von Haunersches Kinderspital
    München, Germany
  • Universitaetsklinikum Tuebingen Klinik fuer Kinder- und Jugendmedizin
    Tübingen, Germany
  • University Hospital Wuerzburg
    Würzburg, Germany
  • General Hospital of Attika "Sismanoglio"(Adult CF center, NHS)
    Marousi, Greece
  • Azienda Ospedaliero Universitaria Ospendali Riuniti
    Ancona, Italy
  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
    Florence, Italy
  • IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico
    Genova, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy
  • Centro Regionale Fibrosi Cistica, A.O. Ospedale San Carlo
    Potenza, Italy
  • Azienda Ospedaliera di Verona-Ospedale Civile Maggiore
    Verona, Italy
  • Academic Medical Center
    Amsterdam, Netherlands
  • University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
    Heidelberglaan, Netherlands
  • UMC St. Radboud
    Nijmegen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands

Showing the first 100 of 110 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M; VX17-445-105 Study Group. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct;211(10):1901-1914. doi: 10.1164/rccm.202411-2231OC. PubMed 40209082 ↗
  • Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4. PubMed 37983082 ↗
  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jan 2023, 51 months.

Results were first posted in May 2024, 1 year 3 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 51 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2018
First posted
May 15, 2018
StartActual
Oct 9, 2018
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Results first posted
May 8, 2024
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03525574
Responsible party
Sponsor
First posted
May 15, 2018
Start date
Oct 9, 2018
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Results posted
May 8, 2024
Last update
Sep 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion